Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted
Igår, 02:30
Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted
PR Newswire
BEIJING, SHANGHAI and BOSTON, July 2, 2025
BEIJING , SHANGHAI and BOSTON , July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and has been accepted. According to new regulatory guidelines, the review of JAB-8263's IND application is expected to be completed within 30 working days
Dr. Yinxiang Wang, Chairman and CEO of Jacobio, said: "Autoimmune diseases affect 5%-9% of the global population. Currently, the majority of therapies are monoclonal antibodies administered intravenously, with only a few oral drugs approved. Through our internal translation research and discovery efforts, we intend to expand the therapeutic value of our BET inhibitor from oncology to autoimmune diseases, ultimately benefiting a broader patient population."
Previously, Jacobio has completed phase I clinical trials of JAB-8263 for solid tumor and hematological malignancies in both China and the United States . Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed that JAB-8263 demonstrated good tolerability.
About JAB-8263
JAB-8263 is an orally administered, highly potent BET inhibitor independently developed by Jacobio Pharma. Its safety and pharmacokinetics have been evaluated in early phase trials in China and the United States . JAB-8263 was well tolerated and exhibited a favorable PK profile. Jacobio is investigating the potential of JAB-8263 in solid tumors and autoimmune diseases.
About Jacobio Pharma
Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company's core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio's R&D centers are in Beijing , Shanghai ( China ), and Boston ( USA ). Clinical trials are conducted at over 180 sites in China , more than 30 sites in the USA , and over 10 sites across several European countries. For more information, please visit: http://www.jacobiopharma.com
SOURCE Jacobio Pharma
Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted
Igår, 02:30
Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted
PR Newswire
BEIJING, SHANGHAI and BOSTON, July 2, 2025
BEIJING , SHANGHAI and BOSTON , July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and has been accepted. According to new regulatory guidelines, the review of JAB-8263's IND application is expected to be completed within 30 working days
Dr. Yinxiang Wang, Chairman and CEO of Jacobio, said: "Autoimmune diseases affect 5%-9% of the global population. Currently, the majority of therapies are monoclonal antibodies administered intravenously, with only a few oral drugs approved. Through our internal translation research and discovery efforts, we intend to expand the therapeutic value of our BET inhibitor from oncology to autoimmune diseases, ultimately benefiting a broader patient population."
Previously, Jacobio has completed phase I clinical trials of JAB-8263 for solid tumor and hematological malignancies in both China and the United States . Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed that JAB-8263 demonstrated good tolerability.
About JAB-8263
JAB-8263 is an orally administered, highly potent BET inhibitor independently developed by Jacobio Pharma. Its safety and pharmacokinetics have been evaluated in early phase trials in China and the United States . JAB-8263 was well tolerated and exhibited a favorable PK profile. Jacobio is investigating the potential of JAB-8263 in solid tumors and autoimmune diseases.
About Jacobio Pharma
Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company's core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio's R&D centers are in Beijing , Shanghai ( China ), and Boston ( USA ). Clinical trials are conducted at over 180 sites in China , more than 30 sites in the USA , and over 10 sites across several European countries. For more information, please visit: http://www.jacobiopharma.com
SOURCE Jacobio Pharma
Börsen idag
-992x558.webp&w=3840&q=75)
Börsen idag
-992x558.webp&w=3840&q=75)
Börsen idag
Börsen idag
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
